Picard Medical / SynCardia to Present Next Generation Total Artificial Heart Platform at ISHLT 2026 in Toronto

Picard Medical (NYSE American: PMI) will present SynCardia’s next-generation total artificial heart platform at ISHLT 2026 in Toronto on April 24, 2026.

Rhea-AI Summary

Picard Medical (NYSE American: PMI) will present SynCardia’s next-generation total artificial heart platform at ISHLT 2026 in Toronto on April 24, 2026. The poster, titled “The Emperor Total Artificial Heart: A Fully Implantable Solution for End Stage Heart Failure”, highlights ongoing development of a fully implantable TAH.

SynCardia will also exhibit at booth 409, offering clinicians and attendees information on the SynCardia Total Artificial Heart and efforts to expand access to life‑sustaining therapies.

Argus Apr 17 session

-3.07% close to close Open Argus

Details

News Market Reaction – PMI

On Apr 17, the first trading day after this news, PMI closed 3.07% below the previous close.

Data tracked by StockTitan Argus for the Apr 17 session.

Key Figures

Conference year: 2026 Presentation date: April 24, 2026 Presentation time: 4:30 p.m. to 5:30 p.m. +2 more

Conference year

2026

ISHLT Annual Meeting year

Presentation date

April 24, 2026

Poster session at ISHLT 2026

Presentation time

4:30 p.m. to 5:30 p.m.

Poster session window

Booth number

409

SynCardia exhibit booth at ISHLT 2026

Exchange ticker

NYSE American: PMI

Listing for Picard Medical, Inc.

Historical Context

5 past events · Latest: Apr 15

5 events

1. Apr 15

   Clinical case highlight

   24h Move

   -1.8%

   Reported successful bridge-to-transplant case using SynCardia Total Artificial Heart.

2. Apr 02

   Conference keynote

   24h Move

   -9.4%

   Announced COO keynote on next-gen fully implantable heart at AZ Tech Week.

3. Apr 01

   Patient event

   24h Move

   +1.0%

   Planned Voice of the Patient event spotlighting advanced heart failure experiences.

4. Mar 25

   Full-year earnings

   24h Move

   +3.0%

   Reported 2025 revenue growth, higher cash, but wider net loss and need for capital.

5. Mar 20

   Conference data

   24h Move

   +2.7%

   Planned presentation of early preclinical Emperor Total Artificial Heart data at ACC.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

total artificial heart, end stage heart failure, biventricular heart failure, mechanical circulatory support

4 terms

total artificial heart medical

"maker of the world’s first total artificial heart approved by both the U.S. FDA"

A total artificial heart is a surgically implanted mechanical device that replaces the heart’s two main pumping chambers and takes over circulation, acting like a continuous pump that keeps blood moving through the body. Investors care because it is a high-cost, high-stakes medical product whose commercial success depends on clinical trial results, regulatory approvals, hospital adoption, reimbursement rules and long-term patient outcomes — factors that drive revenue potential and risk.

end stage heart failure medical

"A Fully Implantable Solution for End Stage Heart Failure” during the Total Artificial"

End stage heart failure is the point at which the heart can no longer pump enough blood to meet the body's needs despite maximal medical treatment, often requiring advanced interventions such as mechanical pumps, heart transplant, or palliative care. For investors, it signals a high unmet medical need and potential market demand for therapies, devices, or supportive services, similar to a crisis that creates urgent demand for new solutions.

biventricular heart failure medical

"patients with end stage biventricular heart failure."

Biventricular heart failure is a condition where both the right and left sides of the heart are weakened and cannot pump blood effectively, like a two-pump system losing power on both ends. It matters to investors because it increases demand for treatments, medical devices, hospital care and long-term therapies, can drive clinical-trial activity and regulatory decisions, and may affect costs and revenue for companies in cardiovascular drugs, devices and healthcare services.

mechanical circulatory support medical

"advances in transplantation and mechanical circulatory support."

Mechanical circulatory support are medical devices that help or take over the heart’s job of moving blood around the body, ranging from temporary external pumps to implanted pumps that assist one or both sides of the heart. For investors, these devices matter because their use drives sales, regulatory scrutiny, reimbursement decisions and long‑term healthcare costs; think of them as a backup engine for a failing heart whose adoption and outcomes influence a company’s market opportunity and risk profile.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Picard to showcase the SynCardia TAH and next-generation innovation 

TUCSON, Ariz., April 16, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard Medical” or the “Company”), parent company of SynCardia Systems, LLC, (“SynCardia”) maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced its participation in the International Society for Heart and Lung Transplantation (“ISHLT”) 2026 Annual Meeting, to be held at the Metro Toronto Convention Centre in Toronto, Canada.

The ISHLT Annual Meeting is a leading global forum for clinicians, researchers and industry participants focused on the treatment of advanced heart and lung failure, featuring the latest clinical data, emerging technologies and advances in transplantation and mechanical circulatory support.

Andre R. Simon, Vice President of Clinical Affairs at SynCardia, will present a poster titled, “The Emperor Total Artificial Heart: A Fully Implantable Solution for End Stage Heart Failure” during the Total Artificial Heart and Emerging Circulatory Support Technologies poster session. The presentation will highlight ongoing development of the next-generation, fully implantable total artificial heart platform.

• Date: April 24, 2026
  
• Time: 4:30 p.m. to 5:30 p.m.
  
• Location: Poster Hall
  
  

In addition to the scientific presentation, SynCardia will exhibit at booth 409, where attendees can learn more about the SynCardia Total Artificial Heart and ongoing efforts to expand access to life sustaining therapies for patients with end stage biventricular heart failure.

Participation in ISHLT 2026 underscores Picard Medical’s continued engagement with the global clinical community and its commitment to advancing innovation in mechanical circulatory support through scientific exchange and collaboration.

About The International Society for Heart and Lung Transplantation

ISHLT is a global, multidisciplinary professional organization dedicated to improving outcomes for patients with advanced heart and lung disease through transplantation, mechanical circulatory support, and innovative therapies. Founded in 1981, ISHLT brings together more than 3,600 members across over 60 countries, including physicians, researchers and allied health professionals, and serves as a leading forum for advancing clinical science, professional standards and education in the field.

About Picard Medical and SynCardia

Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the STAH is the most widely used and extensively studied artificial heart in the world. For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”) at www.sec.gov.

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Additional information about the Company, including risk factors that may affect the Company’s business, financial condition, and results of operations, is contained in the Company's filings with the SEC, including the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available free of charge on the SEC’s website at http://www.sec.gov and on the Company's investor relations website at https://picardmedical.com/.

Contact:

Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com

Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com

General/Media
Brittany Lanza
blanza@syncardia.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Picard Medical (PMI) present SynCardia’s poster at ISHLT 2026?

Picard Medical will present on April 24, 2026 from 4:30 p.m. to 5:30 p.m.. According to the company, the poster appears in the Total Artificial Heart and Emerging Circulatory Support Technologies session in Poster Hall, Toronto.

What is the title of the SynCardia poster Picard Medical (PMI) is presenting at ISHLT 2026?

The poster is titled “The Emperor Total Artificial Heart: A Fully Implantable Solution for End Stage Heart Failure.” According to the company, it highlights development of a next‑generation fully implantable total artificial heart platform.

Where can ISHLT 2026 attendees find SynCardia exhibits from Picard Medical (PMI)?

SynCardia will exhibit at booth 409 at the Metro Toronto Convention Centre. According to the company, booth materials will cover the SynCardia Total Artificial Heart and access efforts for patients with end‑stage biventricular heart failure.

Who is presenting Picard Medical’s (PMI) SynCardia poster at ISHLT 2026?

Andre R. Simon, Vice President of Clinical Affairs at SynCardia, will present the poster. According to the company, he will discuss ongoing development of the next‑generation fully implantable total artificial heart platform.

What will Picard Medical (PMI) emphasize about SynCardia’s technology at ISHLT 2026?

Picard Medical will emphasize development of a next‑generation, fully implantable total artificial heart. According to the company, the presentation and exhibit focus on clinical innovation and expanding access to life‑sustaining therapies.